Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.
Does Syros Pharmaceuticals, Inc. (SYRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Syros Pharmaceuticals, Inc. (SYRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.